Study of LY4050784, a Targeted SMARCA2BRM Inhibitor, In Advanced or Metastatic Solid Tumors with SMARCA4BRG1 Alterations

What this Trial Is About

Researchers are studying LY4050784, a drug being tested for safety, tolerability, and effectiveness in people with locally advanced or metastatic solid tumors that have a specific genetic alteration called SMARCA4 also known as BRG1. This study includes participants who have previously received, do not qualify for, or refuse standard treatments, or when no standard therapy is available. The trial is divided into two parts phase Ia, which focuses on finding the right dose, and phase Ib, which optimizes and expands the dose. The study may last up to about four years. Participants receive LY4050784 orally in different doses and combinations. Some receive LY4050784 alone, while others receive it combined with other anticancer drugs such as pembrolizumab, pemetrexed, cisplatin, carboplatin, paclitaxel, or nab-paclitaxel. The combinations are given in 21-day treatment cycles, continuing until certain criteria are met. The study includes evaluation of escalating doses and comparison of multiple doses during the dose-escalation and dose-expansion phases. During the trial, participants are monitored for side effects, how well they tolerate the treatment, and the drugs impact on their tumors. Researchers measure treatment-emergent adverse events, serious adverse events, and antitumor activity including response rates. They assess drug levels in the blood and how the body processes the drug. Regular safety and efficacy evaluations occur throughout the study, which may last up to approximately four years from the start. Participants overall health and tumor response are tracked closely during this time.

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors